Clinical Use of rituximab in patients with HIV related lymphoma and multicentric Castleman's disease

Current Drug Delivery

Volumn 9, Issue 1, 2012, Pages 41-51

  Reid, Erin ^a   Nooka, Ajay ^b   Blackmon, Jawaunna ^b   Lechowicz, Mary Jo ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

AIDS; AIDS related lymphoma; Bortezomib; CHOP; CODOX IVAC; Dose adjusted EPOCH; HAART; Hepatitis B; Hepatitis C; HIV; JC polyoma virus associated progressive multifocal leukoencephalopathy; Kaposi sarcoma; Lymphoma; Magrath regimen; Multicentric castleman's disease; Non hodgkin lymphoma; Rituximab

Indexed keywords

ANTHRACYCLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINBLASTINE; VINCRISTINE;

AIDS RELATED LYMPHOMA; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CRYPTOSPORIDIOSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; ENCEPHALITIS; FEBRILE NEUTROPENIA; FOLLICULAR LYMPHOMA; GRAM NEGATIVE INFECTION; HEART DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; INFECTION; INFECTIOUS COMPLICATION; JC VIRUS; KAPOSI SARCOMA; LARGE CELL LYMPHOMA; LIVER TOXICITY; LUNG DISEASE; MIXED INFECTION; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SEPSIS; SINGLE DRUG DOSE; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 83455212525     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112798376005     Document Type: Review

References (73)

1. Grillo-Lopez, A.J. Rituximab: an insider's historical perspective. Semin. Oncol., 2000, 27(6 Suppl 12), 9-16.
2. Maloney, D. G.; Smith, B.; Rose, A. Rituximab: mechanism of action and resistance. Semin. Oncol., 2002, 29(1 Suppl 2), 2-9.
3. McLaughlin, P.; Grillo-Lopez, A.J.; Link, B.K.; Levy, R.; Czuczman, M.S.; Williams, M.E.; Heyman, M.R.; Bence-Bruckler, I.; White, C.A.; Cabanillas, F.; Jain, V.; Ho, A.D.; Lister, J.; Wey, K.; Shen, D.; Dallaire, B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol., 1998, 16(8), 2825-2833.
4. Coiffier, B.; Lepage, E.; Brière, J.; Herbrecht, R.; Tilly, H.; Bouabdallah, R.; Morel, P.; Van Den Neste, E.; Salles, G.; Gaulard, P.; Reyes, F.; Lederlin, P.; Gisselbrecht, C. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. New Engl. J. Med., 2002, 346 (4), 235-242.
5. Marcus, R.; Imrie, K.; Belch, A.; Cunningham, D.; Flores, E.; Catalano, J.; Solal-Celigny, P.; Offner, F.; Walewski, J.; Raposo, J.; Jack, A.; Smith, P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 2005, 105 (4), 1417-1423.
6. Gribben, J.; La Casse, A., Clinical manifestations, staging, and treatment of non-Hodgkin's lymphoma. In Hematology: Basic Principles and Practice, 4th ed.; Hoffman, R.; Benz, E. J.; Shattil, S., Eds. Elsevier Churchill Livingstone: Philadelphia, 2005.
7. Habermann, T. M.; Weller, E. A.; Morrison, V. A.; Gascoyne, R. D.; Cassileth, P. A.; Cohn, J. B.; Dakhil, S. R.; Woda, B.; Fisher, R. I.; Peterson, B. A.; Horning, S. J., Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. J. Clin. Oncol., 2006, 24 (19), 3121-3127.
8. Pfreundschuh, M.; Trümper, L.; Österborg, A.; Pettengell, R.; Trneny, M.; Imrie, K.; Ma, D.; Gill, D.; Walewski, J.; Zinzani, P.-L.; Stahel, R.; Kvaloy, S.; Shpilberg, O.; Jaeger, U.; Hansen, M.; Lehtinen, T.; López-Guillermo, A.; Corrado, C.; Scheliga, A.; Milpied, N.; Mendila, M.; Rashford, M.; Kuhnt, E.; Loeffler, M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol., 2006, 7(5), 379-391.
9. Sehn, L. H.; Donaldson, J.; Chhanabhai, M.; Fitzgerald, C.; Gill, K.; Klasa, R.; MacPherson, N.; O'Reilly, S.; Spinelli, J. J.; Sutherland, J.; Wilson, K. S.; Gascoyne, R. D.; Connors, J. M. Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia. J. Clin. Oncol., 2005, 23(22), 5027-5033.
10. Coiffier, B.; Thieblemont, C.; Van Den Neste, E.; Lepeu, G.; Plantier, I.; Castaigne, S.; Lefort, S.; Marit, G.; Macro, M.; Sebban, C.; Belhadj, K.; Bordessoule, D.; Fermé, C.; Tilly, H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 2010, 116(12), 2040-2045.
11. Gonzalez, H.; Bolgert, F.; Camporo, P.; Leblond, V. Progressive multifocal leukoencephalitis (PML) in three patients treated with standard-dose fludarabine (FAMP). Hematol. Cell Ther., 1999, 41(4), 183.
12. Astrom, K.; Mancall, E.; Richardson, E., Progressive Multifocal Leuko-encephalopathy. Brain, 1958, 81 (1), 93-111.
13. Berger, J. R.; Kaszovitz, B.; Post, M. J.; Dickinson, G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann. Intern. Med., 1987, 107(1), 78.
14. Holman, R. C.; Janssen, R. S.; Buehler, J. W.; Zelasky, M. T.; Hooper, W. C. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology, 1991, 41(11), 1733-1736.
15. Goldberg, S.L.; Pecora, A.L.; Alter, R.S.; Kroll, M.S.; Rowley, S. D.; Waintraub, S.E.; Imrit, K.; Preti, R.A., Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood, 2002, 99(4), 1486-1488.
16. Carson, K.R.; Evens, A.M.; Richey, E.A.; Habermann, T.M.; Focosi, D.; Seymour, J.F.; Laubach, J.; Bawn, S.D.; Gordon, L.I.; Winter, J.N.; Furman, R.R.; Vose, J.M.; Zelenetz, A.D.; Mamtani, R.; Raisch, D.W.; Dorshimer, G.W.; Rosen, S.T.; Muro, K.; Gottardi-Littell, N.R.; Talley, R.L.; Sartor, O.; Green, D.; Major, E.O.; Bennett, C.L., Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood, 2009, 113(20), 4834-4840.
17. Carson, K. R.; Focosi, D.; Major, E. O.; Petrini, M.; Richey, E. A.; West, D. P.; Bennett, C.L. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol., 2009, 10(8), 816-824.
18. Levine, A. M. A phase II trial of pegylated doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in patients with newly diagnosed AIDS-associated B-cell non-Hodgkin's lymphoma (ARL): An AIDS Malignancy Consortium trial (AMC 047). In 2010 ASCO Annual Meeting, J. Clin. Oncol., 2010, 28:15s.
19. Lubel, J. S.; Angus, P. W. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: Diagnosis and management. J. Gastroenterol. Hepatol., 2010, 25(5), 864-871.
20. Liu, C.-J.; Chen, P.-J.; Chen, D.-S.; Kao, J.-H. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol. Int., 2011, 1-11.
21. Yeo, W.; Chan, T. C.; Leung, N. W. Y.; Lam, W. Y.; Mo, F. K. F.; Chu, M. T.; Chan, H. L. Y.; Hui, E. P.; Lei, K. I. K.; Mok, T. S. K.; Chan, P. K. S. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. J. Clin. Oncol., 2009, 27(4), 605-611.
22. Hanbali, A.; Khaled, Y. Incidence of hepatitis B reactivation following Rituximab therapy. Am. J. Hematol., 2009, 84 (3), 195.
23. Ziakas, P. D.; Karsaliakos, P.; Mylonakis, E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica, 2009, 94(7), 998-1005.
24. Ennishi, D.; Maeda, Y.; Niitsu, N.; Kojima, M.; Izutsu, K.; Takizawa, J.; Kusumoto, S.; Okamoto, M.; Yokoyama, M.; Takamatsu, Y.; Sunami, K.; Miyata, A.; Murayama, K.; Sakai, A.; Matsumoto, M.; Shinagawa, K.; Takaki, A.; Matsuo, K.; Kinoshita, T.; Tanimoto, M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood, 2010, 116(24), 5119-5125.
25. Nooka, A.; Shenoy, P. J.; Sinha, R.; Lonial, S.; Flowers, C. R. Hepatitis C Reactivation in Patients Who Have Diffuse Large BCell Lymphoma Treated With Rituximab: A Case Report and Review of Literature. Clin. Lymphoma Myeloma Leuk., 2011, 11(5): 379-384.
26. Ziegler, J. L.; Beckstead, J. A.; Volberding, P. A.; Abrams, D. I.; Levine, A. M.; Lukes, R. J.; Gill, P. S.; Burkes, R. L.; Meyer, P. R.; Metroka, C. E.; Mouradian, J.; Moore, A.; Riggs, S. A.; Butler, J. J.; Cabanillas, F. C.; Hersh, E.; Newell, G. R.; Laubenstein, L. J.; Knowles, D.; Odajnyk, C.; Raphael, B.; Koziner, B.; Urmacher, C.; Glarkson, B. D. Non-Hodgkin's Lymphoma in 90 Homosexual Men. New Engl. J. Med., 1984, 311(9), 565-570.
27. Biggar, R. J.; Rabkin, C. S. The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr. Opin. Oncol., 1992, 4(5),883-893.
28. Engels, E. A.; Pfeiffer, R. M.; Goedert, J. J.; Virgo, P.; McNeel, T. S.; Scoppa, S. M.; Biggar, R. J. Trends in cancer risk among people with AIDS in the United States 1980-2002. Aids, 2006, 20(12): 1645.
29. Diebold, J.; Raphael, M.; PrACvot, S.; Audouin, J. Lymphomas associated with HIV infection. Cancer Surv., 1997, 30, 263-293.
30. Rossi, G.; Donisi, A.; Casari, S.; Re, A.; Cadeo, G.; Carosi, G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virusrelated systemic non-Hodgkin lymphoma. Cancer, 1999, 84(5), 425-430.
31. Seneviratne, L.; Espina, B. M.; Nathwani, B. N.; Chan, J. A.; Brynes, R. K.; Levine, A. M. Clinical, immunologic, and pathologic correlates of bone marrow involvement in 291 patients with acquired immunodeficiency syndrome-related lymphoma. Blood, 2001, 98(8), 2358-2363.
32. Kaplan, L. D.; Straus, D. J.; Testa, M. A.; Von Roenn, J.; Dezube, B. J.; Cooley, T. P.; Herndier, B.; Northfelt, D. W.; Huang, J.; Tulpule, A.; Levine, A. M. Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus Infection. New Engl. J. Med., 1997, 336 (23), 1641-1648.
33. Little, R. F.; Pittaluga, S.; Grant, N.; Steinberg, S. M.; Kavlick, M. F.; Mitsuya, H.; Franchini, G.; Gutierrez, M.; Raffeld, M.; Jaffe, E. S.; Shearer, G.; Yarchoan, R.; Wilson, W. H. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood, 2003, 101(12), 4653-4659.
34. Antinori, A.; Cingolani, A.; Alba, L.; Ammassari, A.; Serraino, D.; Ciancio, B. C.; Palmieri, F.; De Luca, A.; Larocca, L. M.; Ruco, L.; Ippolito, G.; Cauda, R. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. Aids, 2001, 15(12), 1483-1491.
35. Tirelli, U.; Spina, M.; Jaeger, U.; Nigra, E.; Blanc, P. L.; Liberati, A. M.; Benci, A.; Sparano, J. A. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study. Recent Results Cancer Res., 2002, 159, 149-153.
36. Boué, F.; Gabarre, J.; Gisselbrecht, C.; Reynes, J.; Cheret, A.; Bonnet, F.; Billaud, E.; Raphael, M.; Lancar, R.; Costagliola, D. Phase II Trial of CHOP Plus Rituximab in Patients With HIVAssociated Non-Hodgkin's Lymphoma. J. Clin. Oncol., 2006, 24(25), 4123-4128.
37. Kaplan, L. D.; Lee, J. Y.; Ambinder, R. F.; Sparano, J. A.; Cesarman, E.; Chadburn, A.; Levine, A. M.; Scadden, D. T., Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005, 106(5), 1538-1543.
38. Ribera, J.-M.; Oriol, A.; Morgades, M.; González-Barca, E.; Miralles, P.; López-Guillermo, A.; Gardella, S.; López, A.; Abella, E.; García, M.; on behalf of the Pethema, G. G.; Groups, G. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virusassociated diffuse large B-cell lymphoma: results of a phase II trial. Brit. J. Haematol., 2008, 140 (4), 411-419.
39. Spina, M.; Jaeger, U.; Sparano, J. A.; Talamini, R.; Simonelli, C.; Michieli, M.; Rossi, G.; Nigra, E.; Berretta, M.; Cattaneo, C.; Rieger, A. C.; Vaccher, E.; Tirelli, U. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood, 2005, 105(5), 1891-1897.
40. Ezzat, H.; Filipenko, D.; Vickars, L.; Galbraith, P.; Li, C.; Murphy, K.; Montaner, J. S.; Harris, M.; Hogg, R. S.; Vercauteren, S.; Leger, C. S.; Zypchen, L.; Leitch, H. A., Improved survival in HIVassociated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin. Trials, 2007, 8(3):132-144.
41. Sparano, J. A.; Lee, J. Y.; Kaplan, L. D.; Levine, A. M.; Ramos, J. C.; Ambinder, R. F.; Wachsman, W.; Aboulafia, D.; Noy, A.; Henry, D. H.; Von Roenn, J.; Dezube, B. J.; Remick, S. C.; Shah, M. H.; Leichman, L.; Ratner, L.; Cesarman, E.; Chadburn, A.; Mitsuyasu, R.; Consortium, f.t.A.M., Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIVassociated B-cell non-Hodgkin lymphoma. Blood, 2010, 115(15), 3008-3016.
42. Dunleavy, K.; Little, R.; Gea-Banacloche, J.; Grant, N.; Steinberg, S.; Yarchoan, R.; Pittaluga, S.; Jaffe, E.; Janik, J.; Wilson, W. H., Abbreviated Treatment with Short-Course Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Is Highly Effective in AIDSRelated Lymphoma (ARL). ASH Annual Meeting Abstracts 2004, 104 (11), 3111.
43. Dunleavy, K.; Wilson, W. H.; Kaplan, L. D., The case for rituximab in AIDS-related lymphoma. Blood, 2006, 107(7), 3014-3015.
44. Dunleavy, K.; Little, R. F.; Grant, N.; Wayne, A. S.; Pittaluga, S.; Tay, K.; Shovlin, M.; Steinberg, S. M.; Jaffe, E. S.; Janik, J.; Wilson, W. H. In Dose-Adjusted Epoch With Rituximab (Da_Epoch-R) Has High Efficacy And Low Toxicity In Young Adults With Newly Diagnosed Burkitt Lymphoma: A Prospective Study Of 25 Patients, 3rd International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin's Lymphoma, Frankfurt, Germany, Frankfurt, Germany, 2009; p. 87.
45. Lacasce, A.; Howard, O.; Li, S.; Fisher, D.; Weng, A.; Neuberg, D.; Shipp, M. Modified Magrath Regimens for Adults with Burkitt and Burkitt-Like Lymphomas: Preserved Efficacy with Decreased Toxicity. Leuk. Lymph., 2004, 45(4), 761-767.
46. Magrath, I.; Adde, M.; Shad, A.; Venzon, D.; Seibel, N.; Gootenberg, J.; Neely, J.; Arndt, C.; Nieder, M.; Jaffe, E.; Wittes, R.; Horak, I. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J. Clin. Oncol., 1996, 14(3), 925-934.
47. Noy, A.; Kaplan, L.; Lee, J. Feasibility and Toxicity of a Modified Dose Intensive R-CODOX-M/IVAC for HIV-Associated Burkitt and Atypical Burkitt Lymphoma(BL): Preliminary Results of a Prospective Multicenter Phase II Trial of the AIDS Malignancy Consortium (AMC). ASH Annual Meeting Abstracts 2009, 114 (22), 3673.
48. Fätkenheuer, G.; Morgades, M.; Wyen, C.; Oriol, A.; Müller, M.; Grande, C.; Hentrichm, M.; Esteve, J.; Hoffmann, C.; Ribera, J. In High-dose MTX-based Chemotherapy including Rituximab Is Highly Effective in HIV+ Patients with Burkitt's Lymphoma, 18th Conference on Retroviruses and Opportunistic Infections, Boston, Boston, 2011; p. 860.
49. Stebbing, J.; Pantanowitz, L.; Dayyani, F.; Sullivan, R. J.; Bower, M.; Dezube, B. J., HIV-associated multicentric Castleman's disease. Am. J. Hematol., 2008, 83(6), 498-503.
50. Bower, M.; Powles, T.; Williams, S.; Davis, T. N.; Atkins, M.; Montoto, S.; Orkin, C.; Webb, A.; Fisher, M.; Nelson, M.; Gazzard, B.; Stebbing, J.; Kelleher, P. Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease. Ann. Inter. Med., 2007, 147(12), 836-839.
51. Michot, J. M.; Gerard, M., Laurence; Fieschi, C.; Burcheri, S.; Oksenhendler, E.; Galicier, L. Protective Effect of Rituximab Against Lymphoma Risk In HIV-Associated Multicentric Castleman Disease. ASH Annual Meeting Abstracts 2010, 116 (21), 2869.
52. Hoffmann, C.; Müller, M.; Schmid, H.; Teutsch, C.; van Lunzen, J.; Wolf, T.; Esser, S.; Wyen, C. B. J; Arastéh, K. In Improved Outcome in Patients with HIV-associated Multicentric Castleman's Disease during Recent Years: An Effect of Rituximab?, 18th Conference on Retroviruses and Opportunistic Infections, Boston, Boston, 2011; p. 861.
53. Wolach, O.; Bairey, O.; Lahav, M., Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine, (Baltimore) 2010, 89(5), 308-318.
54. Spina, M.; Gloghini, A.; Tirelli, U.; Carbone, A. Therapeutic options for HIV-associated lymphomas. Exp. Opin. Pharmacother., 2010, 11(15):2471-2481.
55. Armand, P.; Gannamaneni, S.; Kim, H. T.; Cutler, C. S.; Ho, V. T.; Koreth, J.; Alyea, E. P.; LaCasce, A. S.; Jacobsen, E. D.; Fisher, D. C.; Brown, J. R.; Canellos, G. P.; Freedman, A. S.; Soiffer, R. J.; Antin, J. H. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. J. Clin. Oncol., 2008, 26(35), 5767-5774.
56. Stallone, G.; Schena, A.; Infante, B.; Di Paolo, S.; Loverre, A.; Maggio, G.; Ranieri, E.; Gesualdo, L.; Schena, F. P.; Grandaliano, G. Sirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients. New Engl. J. Med., 2005, 352(13), 1317-1323.
57. El-Salem, M.; Raghunath, P. N.; Marzec, M.; Liu, X.; Kasprzycka, M.; Robertson, E.; Wasik, M. A. Activation of mTORC1 Signaling Pathway in AIDS-Related Lymphomas. Am. J. Pathol., 2009, 175(2), 817-824.
58. Ciechanover, A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J., 1998, 17(24), 7151-7160.
59. Myung, J.; Kim, K. B.; Crews, C. M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev., 2001, 21(4), 245-273.
60. Hideshima, T.; Mitsiades, C.; Akiyama, M.; Hayashi, T.; Chauhan, D.; Richardson, P.; Schlossman, R.; Podar, K.; Munshi, N. C.; Mitsiades, N.; Anderson, K. C. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood, 2003, 101(4), 1530-1534.
61. Bross, P. F.; Kane, R.; Farrell, A. T.; Abraham, S.; Benson, K.; Brower, M. E.; Bradley, S.; Gobburu, J. V.; Goheer, A.; Lee, S. L.; Leighton, J.; Liang, C. Y.; Lostritto, R. T.; McGuinn, W. D.; Morse, D. E.; Rahman, A.; Rosario, L. A.; Verbois, S. L.; Williams, G.; Wang, Y. C.; Pazdur, R. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res., 2004, 10 (12 Pt 1), 3954-3964.
62. Richardson, P. G.; Weller, E.; Lonial, S.; Jakubowiak, A. J.; Jagannath, S.; Raje, N. S.; Avigan, D. E.; Xie, W.; Ghobrial, I. M.; Schlossman, R. L.; Mazumder, A.; Munshi, N. C.; Vesole, D. H.; Joyce, R.; Kaufman, J. L.; Doss, D.; Warren, D. L.; Lunde, L. E.; Kaster, S.; DeLaney, C.; Hideshima, T.; Mitsiades, C. S.; Knight, R.; Esseltine, D.-L.; Anderson, K. C. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood, 2010, 116 (5), 679-686.
63. Bibas, M.; Grisetti, S.; Alba, L.; Picchi, G.; Del Nonno, F.; Antinori, A., Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, Oxaliplatin, Cytarabine, and Pegfilgrastim Chemotherapy and Lenalidomide Alone. J. Clin. Oncol., 2010, 28 (34), e704-e708.
64. Bose, P.; Thompson, C.; Gandhi, D.; Ghabach, B.; Ozer, H. AIDSrelated plasmablastic lymphoma with dramatic, early response to bortezomib. Eur. J. Haematol., 2009, 82(6), 490-492.
65. http://www.clincialtrials.gov. (accessed July 4).
66. Sarosiek, K. A.; Cavallin, L. E.; Bhatt, S.; Toomey, N. L.; Natkunam, Y.; Blasini, W.; Gentles, A. J.; Ramos, J. C.; Mesri, E. A.; Lossos, I. S. Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc. Natl. Acad. Sci. USA, 2010, 107(29), 13069-13074.
67. Yu, L.; Mohanram, V.; Simonson, O. E.; Smith, C. I. E.; Spetz, A.-L.; Mohamed, A. J. Proteasome inhibitors block HIV-1 replication by affecting both cellular and viral targets. Biochem. Biophys. Res. Commun., 2009, 385 (1), 100-105.
68. Sunil, M.; Mixon, T.; Reid, E.; Lechowicz, M. J. HIV Related Hodgkin's Lymphoma in the HAART Era: A Comprehensive Review and Meta-Analysis of Response and Survival Rates. ASH Annual Meeting Abstracts 2009, 114 (22), 1652.
69. Rapezzi, D.; Ugolini, D.; Ferraris, A.M.; Racchi, O.; Gaetani, G.F. Histological subtypes of Hodgkin's disease in the setting of HIV infection. Ann. Hematol., 2001, 80 (6), 340-344.
70. Powles, T.; Bower, M., HIV-associated Hodgkin's disease. Int. J. STD AIDS 2000, 11(8), 492-494.
71. Gerard, L.; Galicier, L.; Boulanger, E.; Quint, L.; Lebrette, M. G.; Mortier, E.; Meignin, V.; Oksenhendler, E., Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. Aids, 2003, 17(1), 81-87.
72. Wedgwood, A.R.; Fanale, M.A.; Fayad, L.E.; McLaughlin, P.; Hagemeister, F.B.; Pro, B.; Romaguera, J.; Rodriguez, M.A.; Samaniego, F.; Younes, A., Rituximab + ABVD Improves Event-Free Survival (EFS) in Patients with Classical Hodgkin Lymphoma in All International Prognostic Score (IPS) Groups and in Patients Who Have PET Positive Disease after 2 3 Cycles of Therapy. ASH Annual Meeting Abstracts 2007, 110 (11), 215.
73. Oki, Y.; Younes, A. Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma? Current Hematol. Malign Rep., 2010, 5 (3), 135-139.